Meeting
2014 ASCO Annual Meeting
DUO: A phase 3 trial of the PI3K-δ,γ inhibitor IPI-145 versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Authors
Ian Flinn
Sarah Cannon Research Institute, Nashville, TN
Ian Flinn , Ulrich Jäger , Fritz Offner , Florence Cymbalista , Michael Hallek , Federico Caligaris-Cappio , Julio Delgado , Peter Hillmen , Matthew Steven Davids , David Donald Wright , James H. Essell , Bartrum W Baker , Walter Cosolo , Patrick Francis Kelly , Patricia Harris , Lixin Han , Fiona Patterson , Stephan Stilgenbauer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT02004522
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS7122)
DOI
10.1200/jco.2014.32.15_suppl.tps7122
Abstract #
TPS7122
Poster Bd #
405B
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE.
First Author: John C. Byrd
Poster
2015 ASCO Annual Meeting
![MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM).](https://d201v5jt9ylckg.cloudfront.net/156/9331/115230/115230_poster_pv.jpg)
MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM).
First Author: Paul G. Richardson
Poster
2013 ASCO Annual Meeting
A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).
First Author: Ian Flinn
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of trifluridine/tipiracil in combination with bevacizumab in older and younger patients with refractory metastatic colorectal cancer: A subgroup analysis of the phase 3 SUNLIGHT trial.
First Author: Julien Taieb